Premium
Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine‐induced weight gain
Author(s) -
Park YoungMin,
Choi JungEun,
Kang SeungGul,
Koo SeungHoi,
Kim Leen,
Geum Dongho,
Lee HeonJeong
Publication year - 2011
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1210
Subject(s) - cannabinoid , olanzapine , gene , genetics , weight gain , receptor , biology , medicine , endocrinology , schizophrenia (object oriented programming) , body weight , psychiatry
Background Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight. Methods In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene ( CNR1 ) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment. Weight and height were measured prior to starting olanzapine and again after long‐term treatment in 78 patients with schizophrenia. CNR1 polymorphisms were genotyped using PCR‐RFLP methods. Results The three CNR1 polymorphisms were not associated with body weight changes from baseline to the endpoint after olanzapine treatment ( p > 0.05). There were also no significant differences in genotype, allele, or haplotype frequencies between the high weight gain (at least 7%) and low weight gain (less than 7%) groups. Conclusion Within the limitations imposed by the smallness of the clinical sample, our findings suggest that CNR1 polymorphisms are not associated with olanzapine‐induced weight gain. Copyright © 2011 John Wiley & Sons, Ltd.